Pfizer CEO Albert Bourla emphasized the need for government support to boost U.S. biotech competitiveness relative to China and expressed readiness among drugmakers to collaborate with the Trump administration on expanding direct-to-consumer drug sales in the U.S. This approach aims to enhance affordability and market access, with industry leaders discussing strategies to bypass pharmacy benefit managers and offer discounted medications. Bourla also highlighted active engagement at high government levels on policy initiatives affecting drug pricing and delivery models.